In Depth 30 Jan 2026 Johnson & Johnson’s pipeline strategy: What does 2026 have in store for the big pharma? Discover J&J’s pipeline strategy for 2026 as it it projects that its sales for the year will be between $100 billion and $101 billion. January 30, 2026 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2026 U.K. biotech ends on a high note in 2025 despite plummeting investments, report reveals The BIA 2025 report has revealed that despite a decline investments, the U.K. biotech sector has shown resilience. January 28, 2026 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Webinars Produced by Inpart 26 Jan 2026Partnering trends and predictions 2026 A data-driven discussion on biopharma partnering trends, exploring dealmaking signals, AI-driven collaboration, and new approaches to R&D and BD landscaping shaping 2026. January 26, 2026 Share WhatsApp Twitter Linkedin Email Produced by Inpart
Best in Biotech 19 Jan 2026 Curing ALS? Ten companies developing new treatments in 2026 Delve into the increasingly dynamic landscape of ALS treatment development with ten companies advancing candidates in 2026. January 19, 2026 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 14 Jan 2026 The AbbVie strategy, a company at an inflection point Look into AbbVie’s strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent cliff. January 14, 2026 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Jan 2026 14 biotech podcasts to tune into in 2026 Here is a list of 14 biotech podcasts to keep you up to date with the latest advances in the biotechnology industry. January 12, 2026 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 7 Jan 2026 Top biotech deals in December 2025 As we head into the 2026, let’s take a look at biotech licensing deals and M&As that were inked in December 2025. January 7, 2026 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Dec 2025 Eight of the biggest immunology and inflammation (I&I) deals in 2025 Discover eight of the biggest immunology and inflammation (I&I) deals in 2025, from early-stage collaborations to late-stage licensing deals. December 17, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 9 Dec 2025 When AI isn’t enough: How physics is shaping the next wave of drug discovery Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech – the AI and physics combo. December 9, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2025 Top biotech deals in November 2025 An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals space in November. December 8, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Playbooks Produced by Inpart 4 Dec 2025Alliance management operations playbook: The path to smarter, streamlined alliance management This playbook serves as a blueprint for deploying operational strategies that empower Alliance Management teams to unlock the full potential of every partnership. December 4, 2025 Share WhatsApp Twitter Linkedin Email Produced by Inpart
In Depth 3 Dec 2025 Boehringer Ingelheim’s pipeline activity: A busy year of dealmaking for the German pharma in 2025 Discover Boehringer Ingelheim’s pipeline focus areas and how its dealmaking in 2025 has expanded its therapeutic arsenal. December 3, 2025 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email